Compare Ambea AB with Similar Stocks
Dashboard
1
Poor long term growth as Operating profit has grown by an annual rate 14.28% of over the last 5 years
2
The company has declared Positive results for the last 6 consecutive quarters
3
With ROE of 13.24%, it has a fair valuation with a 2.11 Price to Book Value
4
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 11,194 Million (Small Cap)
16.00
NA
117.35%
0.83
13.61%
2.15
Revenue and Profits:
Net Sales:
4,193 Million
(Quarterly Results - Dec 2025)
Net Profit:
130 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.23%
0%
-6.23%
6 Months
0%
0%
0.0%
1 Year
18.73%
0%
18.73%
2 Years
104.48%
0%
104.48%
3 Years
294.35%
0%
294.35%
4 Years
184.09%
0%
184.09%
5 Years
75.96%
0%
75.96%
Ambea AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.67%
EBIT Growth (5y)
14.28%
EBIT to Interest (avg)
1.87
Debt to EBITDA (avg)
1.91
Net Debt to Equity (avg)
0.71
Sales to Capital Employed (avg)
1.63
Tax Ratio
23.90%
Dividend Payout Ratio
33.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.59%
ROE (avg)
9.03%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
2.11
EV to EBIT
12.78
EV to EBITDA
5.90
EV to Capital Employed
1.56
EV to Sales
1.03
PEG Ratio
0.71
Dividend Yield
124.26%
ROCE (Latest)
12.23%
ROE (Latest)
13.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
4,193.00
3,637.00
15.29%
Operating Profit (PBDIT) excl Other Income
629.00
620.00
1.45%
Interest
144.00
114.00
26.32%
Exceptional Items
0.00
0.00
Consolidate Net Profit
130.00
147.00
-11.56%
Operating Profit Margin (Excl OI)
56.00%
75.60%
-1.96%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 15.29% vs 6.59% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -11.56% vs 10.53% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
16,039.00
14,195.00
12.99%
Operating Profit (PBDIT) excl Other Income
2,707.00
2,480.00
9.15%
Interest
520.00
464.00
12.07%
Exceptional Items
0.00
-9.00
100.00%
Consolidate Net Profit
665.00
620.00
7.26%
Operating Profit Margin (Excl OI)
74.90%
78.40%
-0.35%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 12.99% vs 6.63% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 7.26% vs 36.26% in Dec 2024
About Ambea AB 
Ambea AB
Pharmaceuticals & Biotechnology
Ambea AB (publ) is a Sweden-based holding company within the care provider group. The Ambea group offers accommodation, support, training and staffing within health and social care. The Group has over 450 units throughout Sweden and in Norway. The Swedish operations comprise the brands Vardaga, Lara and Bemanning. Among other brands, there are Rent a Doctor, Rent a Nurse, Rent a Socionom and Careteam, as well as BoA Mellanvard. The Norwegian operations comprise support and residential care in disabilities and psychiatry through the companies Heimta and Vitale. The Company’s main shareholders are ACTR Holding Ab and Actor General Partner SARL Sweden SCA. It operates Malrettet Intervensjon AS, Elevhalsan, Stod och Resurs AB and Tiltaksgruppa fokus as subsidiaries.
Company Coordinates 
Company Details
Evenemangsgatan 21, 6 tr, Box 1565 , SOLNA None : 171 29
Registrar Details






